NeuroRx Announces ZYESAMI™ (aviptadil, RLF-100) Met the Primary Endpoint of Its Phase 2b/3 Clinical Trial and Also Demonstrated a Meaningful Benefit in Survival from Critical COVID-19 ...Middle East

RADNOR, Pa., March 29, 2021 /PRNewswire/ -- NeuroRx, Inc. today reports 60-day results of the Phase 2b/3 trial of intravenously-administered ZYESAMI™ (aviptadil acetate) for the treatment of respiratory failure in critically-ill patients with COVID-19, which is being developed in...

Hence then, the article about neurorx announces zyesami aviptadil rlf 100 met the primary endpoint of its phase 2b 3 clinical trial and also demonstrated a meaningful benefit in survival from critical covid 19 was published today ( Monday 29/03/2021 - 08:30 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( NeuroRx Announces ZYESAMI™ (aviptadil, RLF-100) Met the Primary Endpoint of Its Phase 2b/3 Clinical Trial and Also Demonstrated a Meaningful Benefit in Survival from Critical COVID-19 )

Also on site :

• Germany’s Merz changes stance on Russia
• Tokyo's Yamanote Line suspended due to power outage
• Tokyo's Yamanote loop line trains out of service due to power outage